A preliminary discussion on carnosine dipeptidase 1 as a potential novel biomarker for the diagnostic and prognostic evaluation of hepatocellular carcinoma.
10.3760/cma.j.cn501113-20230220-00069
- VernacularTitle:肌肽二肽酶作为肝细胞癌诊断及预后评估潜在新型标志物的初步探讨
- Author:
Xin LI
1
;
Yan LI
2
;
Xi LI
2
;
Li Na JIANG
2
;
Li ZHU
2
;
Feng Min LU
3
;
Jing Min ZHAO
1
Author Information
1. The Second Clinical Medicine School of Southern Medical University, Guangzhou 510515, China The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
2. The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
3. Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
- Publication Type:Journal Article
- Keywords:
Biomarker;
Carnosine dipeptidase 1;
Diagnosis;
Hepatocellular carcinoma;
Prognosis
- MeSH:
Humans;
Carcinoma, Hepatocellular/genetics*;
Liver Neoplasms/pathology*;
Prognosis;
Carnosine;
alpha-Fetoproteins/metabolism*;
Biomarkers, Tumor/genetics*;
Liver Cirrhosis/diagnosis*;
ROC Curve
- From:
Chinese Journal of Hepatology
2023;31(6):627-633
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore carnosine dipeptidase 1 (CNDP1) potential value as a diagnostic and prognostic evaluator of hepatocellular carcinoma (HCC). Methods: A gene chip and GO analysis were used to screen the candidate marker molecule CNDP1 for HCC diagnosis. 125 cases of HCC cancer tissues, 85 cases of paracancerous tissues, 125 cases of liver cirrhosis tissues, 32 cases of relatively normal liver tissue at the extreme end of hepatic hemangioma, 66 cases from serum samples of HCC, and 82 cases of non-HCC were collected. Real-time fluorescent quantitative PCR, immunohistochemistry, western blot, and enzyme-linked immunosorbent assay were used to detect the differences in mRNA and protein expression levels of CNDP1 in HCC tissue and serum. Receiver operating characteristic (ROC) curves and Kaplan-Meier survival were used to analyze and evaluate the value of CNDP1 in the diagnosis and prognosis of HCC patients. Results: The expression level of CNDP1 was significantly reduced in HCC cancer tissues. The levels of CNDP1 were significantly lower in the cancer tissues and serum of HCC patients than those in liver cirrhosis patients and normal controls. ROC curve analysis showed that the area under the curve of serum CNDP1 in the diagnosis of HCC patients was 0.753 2 (95% CI 0.676-0.830 5), and the sensitivity and specificity were 78.79% and 62.5%, respectively. The combined detection of serum CNDP1 and serum alpha-fetoprotein (AFP) significantly improved the diagnostic accuracy (AUC = 0.820 6, 95% CI 0.753 5-0.887 8). The diagnostic sensitivity and specificity of serum CNDP1 for AFP-negative HCC patients were 73.68% and 68.75% (AUC = 0.793 1, 95% CI 0.708 8-0.877 4), respectively. In addition, the level of serum CNDP1 distinguished small liver cancer (tumor diameter < 3 cm) (AUC = 0.757 1, 95% CI 0.637 4-0.876 8). Kaplan-Meier survival analysis showed that CNDP1 was associated with a poor prognosis in HCC patients. Conclusion: CNDP1 may be a potential biomarker for the diagnostic and prognostic evaluation of HCC, and it has certain complementarity with serum AFP.
